CSIMarket
 
Compass Therapeutics Inc   (CMPX)
Other Ticker:  
 
 
Price: $2.2900 $0.35 18.041%
Day's High: $2.34 Week Perf: 14.5 %
Day's Low: $ 1.92 30 Day Perf: 44.94 %
Volume (M): 696 52 Wk High: $ 3.62
Volume (M$): $ 1,594 52 Wk Avg: $2.31
Open: $1.92 52 Wk Low: $1.15



 Market Capitalization (Millions $) 292
 Shares Outstanding (Millions) 127
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -41
 Cash Flow (TTM) (Millions $) 14
 Capital Exp. (TTM) (Millions $) 0

Compass Therapeutics Inc
Compass Therapeutics Inc is a biotechnology company focused on developing targeted antibody therapies to treat cancer. The company combines computational biology, antibody drug discovery, and translational medicine to create differentiated antibody therapeutics. Compass Therapeutics aims to develop multi-specific antibodies that can simultaneously target multiple disease-associated antigens, potentially leading to more effective and safer treatments. The company's goal is to address the limitations of traditional monoclonal antibody therapies by utilizing their unique approach to drug discovery and development.


   Company Address: 80 Guest St., Suite 601 Boston 2135 MA
   Company Phone Number: 500-8099   Stock Exchange / Ticker: NASDAQ CMPX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Compass Therapeutics' CTX-8371: Unleashing the Power of Bispecific Antibodies in the Fight Against Cancer

Published Wed, Feb 28 2024 1:00 PM UTC

CTX-8371, a fully-human, tetravalent bispecific antibody, stands out due to its unique mechanism-of-action which entails dual blockade of PD-1 and PD-L1 as well as cleavage of cell surface PD-1. By targeting both PD-1 and its ligand PD-L1, CTX-8371 aims to unleash the immune system's full potential in recognizing and eliminating cancer cells, resulting in enhanced anti-tumor...

Clinical Study

Compass Therapeutics Pioneers Novel Approaches in Oncology Treatment: A Beacon of Hope for Patients

Published Fri, Jan 5 2024 1:00 PM UTC

Compass Therapeutics Provides Corporate Update: Promising Progress in Oncology-focused Biopharmaceutical DevelopmentBOSTON, Jan. 05, 2024 ?? Compass Therapeutics, a clinical-stage biopharmaceutical company specializing in the development of proprietary antibody-based therapeutics, announced significant strides in their quest to combat multiple human diseases. With a specific...

Compass Therapeutics Inc

Compass Therapeutics Inc. Reports Dramatic Operating Shortfall of $-12.598 Million in Fiscal Year 2023

During the past five trading days, shares of Compass Therapeutics Inc have experienced a drop of 2.22%. This decline adds to the company's year-to-date performance, which now stands at -65.83%. However, despite this setback, Compass Therapeutics Inc shares are currently trading 6.3% higher than their 52-week low.
In the competitive world of the Biotechnology & Pharmaceuticals industry, it is not only the larger, more well-known companies that are making waves. Some lesser-known entities, like Compass Therapeutics Inc, are also reporting significant earnings. Recently, CMPX, the parent company of Compass Therapeutics Inc, announced an operating shortfall of $-11.926 million for the third quarter of 2023. This figure represents an improvement compared to the third quarter of 2022, where the operating shortfall was at $-12.598 million.

Compass Therapeutics Inc

Compass Therapeutics Inc Reports Decreased Operating Results for Q2 2023 with a Deficit of $13.337 Million


Introduction
The Biotechnology & Pharmaceuticals sector has always been a bellwether for the stock market, with large-scale companies often taking the spotlight. However, in recent times, smaller businesses are also making their mark. One such company is Compass Therapeutics Inc, which recently reported an operating deficit for the second quarter of 2023. This article delves into the numbers and assesses the impact on investors, while also considering the possibility of future revenue generation.
Operating Deficit and Deterioration
Compass Therapeutics Inc reported an operating deficit of $-13.337 million for the second quarter of 2023, a significant decline from the $-8.987 million deficit reported during the same period in 2022. This indicates a worrying trend in the company's financials, raising concerns among investors.

Compass Therapeutics Inc

Revolutionary Breakthroughs Expected as Compass Therapeutics Inc. Prepares for the 2023 Reporting Season

Exciting Times Ahead for the Stock Market: Compass Therapeutics Inc.
As we approach the beginning of the 2023 reporting season at Compass Therapeutics Inc, stockholders are eagerly anticipating the unveiling of new business models. Despite a recently reported operating shortfall of $-9.711 million, investors remain confident in the company's prospects and its ability to bounce back from its current downturn.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com